单次围术期抗生素可持久改变Roux-en-Y胃旁路术后肠道微生物组
这项前瞻性随机研究将16例Roux-en-Y胃旁路术(RYGB)患者随机分配至单次围术期静脉头孢唑林(n=8)或克林霉素(n=8),在四个时间点采集粪便进行16S rRNA和宏基因组测序。结果显示RYGB在术后2周诱导肠道微生物组显著变化并维持至3个月,而单次围术期抗生素可诱导独特且持久的、抗生素特异性的微生物组改变,克林霉素组双歧杆菌属增加。
要点
- RYGB术后2周肠道微生物组发生显著变化并维持至3个月。
- 单次围术期抗生素可持久改变RYGB术后肠道微生物组。
- 克林霉素组术后3个月双歧杆菌属增加。
核心结论
- RYGB诱导的肠道微生物组变化在术后2周出现并维持至3个月。
- 单次围术期抗生素在RYGB术后诱导独特且持久的、抗生素特异性的肠道微生物组改变。
研究设计与样本
- 前瞻性随机研究,将接受RYGB的患者随机分配至单次围术期静脉头孢唑林(n=8)或克林霉素(n=8)。
- 在术前2周、术前2天、术后2周和术后3个月四个时间点采集粪便样本。
- 共分析来自16例患者的60份粪便样本(-2w n=16;-2d n=15;+2w n=16;+3m n=13),采用Illumina 16S rRNA基因测序和鸟枪法宏基因组测序(MGS)。
主要发现
- 患者中87.5%为女性,平均年龄48.6 ± 12.2岁,术前BMI为50.9 ± 23.3 kg/m2。
- RYGB诱导alpha和beta多样性出现统计学显著差异。
- 抗生素治疗导致术后2周alpha多样性和术后3个月beta多样性出现统计学显著差异。
- MGS显示术后3个月抗生素治疗驱动11个判别性宏基因组组装基因组,包括克林霉素组双歧杆菌属增加。
临床怎么用
- 围术期抗生素选择可能通过肠道微生物组机制影响RYGB术后结局。
- 克林霉素相关双歧杆菌属增加可能改善RYGB的代谢疗效,涉及血压缓解的微生物组驱动机制。
局限性
- 样本量小(每组n=8,共16例患者)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Roux-en-Y gastric bypass (RYGB) significantly alters the gut microbiome and may be a mechanism for post-operative cardiovascular disease improvement. We have previously found an association between the class of peri-operative, intravenous antibiotic administered at the time of RYGB and the resolution rate of hypertension suggesting the gut microbiome as a mechanism. In this study, we performed a prospective study of RYGB to determine if a single intravenous antibiotic could alter the gastrointestinal microbial composition. METHODS: Patients undergoing RYGB were randomized to a single, peri-operative antibiotic of intravenous cefazolin (n = 8) or clindamycin (n = 8). Stool samples were collected from four-time points: 2 weeks pre-op (- 2w), 2 days pre-op (- 2d), 2 weeks post-op (+ 2w) and 3 months post-op (+ 3m). Stool samples were processed for genomic DNA followed by Illumina 16S rRNA gene sequencing and shotgun metagenomic sequencing (MGS). RESULTS: A total of 60 stool samples (- 2w, n = 16; - 2d, n = 15; + 2w, n = 16; + 3m, n = 13) from 16 patients were analyzed. 87.5% of patients were female with an average age of 48.6 ± 12.2 years and pre-operative BMI of 50.9 ± 23.3 kg/m2. RYGB induced statistically significant differences in alpha and beta diversity. There were statistically significant differences in alpha diversity at + 2w and beta diversity at + 3m due to antibiotic treatment. MGS revealed significantly distinct gut microbiota with 11 discriminatory metagenomic assembled genomes driven by antibiotic treatment at 3 months post-op, including increased Bifidobacterium spp. with clindamycin. CONCLUSION: RYGB induces significant changes in the gut microbiome at 2 weeks that are maintained 3 months after surgery. However, the single peri-operative dose of antibiotic administered at the time of RYGB induces unique and persisting changes to the gut microbiome that are antibiotic-specific. Increased Bifidobacterium spp. with clindamycin administration may improve the metabolic efficacy of RYGB when considering gut-microbiome driven mechanisms for blood pressure resolution.
引用
- Fernando DG, Saravia FL, Atkinson SN, et al. A single, peri-operative antibiotic can persistently alter the post-operative gut microbiome after Roux-en-Y gastric bypass. Surg Endosc. 2022. PMID: 35768736. doi:10.1007/s00464-022-09387-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。